Groupe d'Etude en Oncologie du Quebec

Title	Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase II Trial
Protocole ID	SHORT-OPC
ClinicalTrials.gov ID	NCT04178174
Cancer Type(s)	Head and Neck
Phase	Phase II
Stage
Study Type	Clinical
Drug
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City
Principal Investigator	Dr. Houda Bahig
Coordinator	Mom Phat 514-890-8000 poste 11171
Status	Recruiting
Activation Date
Eligibility Criteria	Age ≥18 years Ability to provide written informed consent. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx. Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH) Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition. Primary tumor < 30 cc Planned for curative chemoradiation For females of child-bearing age, a negative pregnancy test
Exclusion Criteria	Previous irradiation of the head and neck (HNC) region Previous surgery of the HNC region (except for incisional or excisional biopsies) Pregnancy or breastfeeding Connective tissue disease Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy. Non-Cisplatin concurrent chemotherapy Prior induction chemotherapy

Groupe d'étude en oncologie du Québec